Effectiveness and Safety of Ustekinumab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

P087 REAL-WORLD EFFECTIVENESS OF USTEKINUMAB IN ULCERATIVE COLITIS

(2020) Simon Hong et al.   INFLAMMATORY BOWEL DISEASES

P737 Ustekinumab induction effectiveness in Crohn’s disease in a real-life cohort

(2020) E Sánchez Rodríguez et al.   Journal of Crohns & Colitis

P697 Efficacy and safety of ustekinumab in Crohn’s disease: A real-world study from Australia

(2020) P Kakkadasam Ramaswamy et al.   Journal of Crohns & Colitis

P507 Ustekinumab: Medium-term outcomes from a UK multicentre real-world cohort

(2020) R Gadhok et al.   Journal of Crohns & Colitis

P484 Effectiveness and safety of ustekinumab in patients with Crohn’s disease: a real-world experience

(2020) D Mohammad et al.   Journal of Crohns & Colitis

P346 Single-centre experience of ustekinumab: Therapeutic drug monitoring in Crohn’s disease patients

(2020) C Liefferinckx et al.   Journal of Crohns & Colitis

P577 Ustekinumab in actual clinical practice: our centre experience

(2020) J M LOPEZ TOBARUELA et al.   Journal of Crohns & Colitis

P575 Real-world effectiveness and safety of ustekinumab for the treatment of refractory Crohn’s disease: The Scottish ustekinumab cohort

(2020) N PLEVRIS et al.   Journal of Crohns & Colitis

P519 Higher anti-TNF α trough levels are not associated with increased radiological response in perianal fistulising Crohn’s disease: A multicentre study

(2020) T LEE et al.   Journal of Crohns & Colitis

P415 The anti-IL-23/IL-12 agent Ustekinumab is an effective and safe induction therapy in patients with Crohn’s disease refractory or intolerant to anti-TNF: a multicentre Italian study

(2020) A Gubbiotti et al.   Journal of Crohns & Colitis

P447 No severe neonatal and maternal complications in inflammatory bowel diseases patients treated with ustekinumab or vedolizumab during pregnancy

(2020) P Wils et al.   Journal of Crohns & Colitis

P344 Effectiveness of ustekinumab in refractory Crohn’s disease: A real-life experience in a tertiary referral centre

(2020) M Truyens et al.   Journal of Crohns & Colitis

P538 Pregnancy outcomes in women with psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis treated with ustekinumab

(2020) A Geldhof et al.   Journal of Crohns & Colitis

Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn’s disease: A multicenter Israeli study

(2020) Ariella Bar-Gil Shitrit et al.   United European Gastroenterology Journal

Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study

(2020) Aurélien Amiot et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor

(2020) Hadrien Alric et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Mo1860 REAL-WORLD LONG-TERM EFFECTIVENESS OF USTEKINUMAB IN CROHN'S DISEASE: RESULTS FROM THE ENEIDA REGISTRY

(2020) Marisa Iborra et al.   GASTROENTEROLOGY

Mo1873 WHICH SECOND-LINE BIOLOGIC AFTER ANTI-TNF FAILURE DURING CROHN'S DISEASE: USTEKINUMAB OR VEDOLIZUMAB, A MULTICENTRE RETROSPECTIVE STUDY

(2020) Cassandra Rayer et al.   GASTROENTEROLOGY

Sa1841 USTEKINUMAB IS SAFE IN ELDERLY CROHN'S DISEASE PATIENTS

(2020) Rajat Garg et al.   GASTROENTEROLOGY

Inflammatory Bowel Disease (IBD) in Pregnancy Clinical Care Pathway – A Report from the American Gastroenterological Association IBD Parenthood Project Working Group

(2019) Uma Mahadevan et al.   GASTROENTEROLOGY

Immunosuppressives and biologics during pregnancy and lactation

(2019) Antonia Puchner et al.   WIENER KLINISCHE WOCHENSCHRIFT

P460 Efficacy of ustekinumab in patients with anti-TNF refractory Crohn’s disease: data from a real-world study in Brazil

(2019) R S Parra et al.   Journal of Crohns & Colitis

P654 Monitoring of drug concentrations to predict remission under ustekinumab induction therapy in Crohn's disease patients

(2019) N Soufflet et al.   Journal of Crohns & Colitis

P561 Impact of ustekinumab TDM on clinical practice: a multi-centre, prospective, cross-sectional observational trial—mUST-Decide

(2019) B Bressler et al.   Journal of Crohns & Colitis

P641 Ustekinumab efficiency as a higher-line therapy in association with serum levels in patients with Crohn’s disease

(2019) M Kolar et al.   Journal of Crohns & Colitis

P540 Therapeutic drug monitoring in ustekinumab: which factors affect trough levels?

(2019) R Theeuwen et al.   Journal of Crohns & Colitis

P668 Ustekinumab induction effectiveness in Crohn’s disease in a real-life cohort

(2019) M Rullan et al.   Journal of Crohns & Colitis

P533 Ustekinumab therapeutic drug monitoring in Crohn’s disease patients with loss of response

(2019) V Heron et al.   Journal of Crohns & Colitis

P586 Comparative effectiveness of vedolizumab and ustekinumab as induction therapy in anti-TNF refractory Crohn’s disease: a multi-centre retrospective cohort study

(2019) T Townsend et al.   Journal of Crohns & Colitis

Ustekinumab Exposure-outcome Analysis in Crohn’s Disease Only in Part Explains Limited Endoscopic Remission Rates

(2019) Bram Verstockt et al.   Journal of Crohns & Colitis

DOP74 Efficacy of ustekinumab in perianal Crohn’s disease: the BioLAP multi-centre observational study

(2019) C Biron et al.   Journal of Crohns & Colitis

Mo1916 – Effectiveness and Safety of Ustekinumab for Crohn’s Disease in Routine Clinical Practice

(2019) Amanda M. Lynn et al.   GASTROENTEROLOGY

Long-term clinical effectiveness of ustekinumab in patients with Crohn’s disease who failed biological therapies: a national cohort study

(2019) Claire Liefferinckx et al.   Journal of Crohns & Colitis

Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn’s disease: results from the ENEIDA registry

(2019) M. Iborra et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Biologics exposure during pregnancy and breastfeeding in a psoriasis patient

(2019) Cristina Mugheddu et al.   Dermatologic Therapy

Effectiveness and safety of Ustekinumab for Crohn's disease; systematic review and pooled analysis of real-world evidence

(2019) Tal Engel et al.   DIGESTIVE AND LIVER DISEASE

IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn’s Disease

(2019) Stephen B Hanauer et al.   Journal of Crohns & Colitis

Ustekinumab for Crohn’s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study

(2019) Vince B C Biemans et al.   Journal of Crohns & Colitis

Ustekinumab for Crohn’s disease: a nationwide real-life cohort study from Finland (FINUSTE)

(2019) Anja Eberl et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Ustekinumab and Pregnancy: Continue or Cease Before You Conceive?

(2019) Turki AlAmeel et al.   GASTROENTEROLOGY

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2019) Bruce E. Sands et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ustekinumab: “Real-world” outcomes and potential predictors of nonresponse in treatment-refractory Crohn’s disease

(2019) Peter Hoffmann et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Pharmacokinetics and Exposure-Response Relationships of Ustekinumab in Patients With Ulcerative Colitis: Results From the UNIFI Induction and Maintenance Studies

(2019) Omoniyi J. Adedokun et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Effectiveness and safety of Ustekinumab for the treatment of Crohn’s disease in real-life experiences: a meta-analysis of observational studies

(2019) Fabio Salvatore Macaluso et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Eficacia y seguridad de ustekinumab en la práctica clínica real. Estudio multicéntrico retrospectivo. Cohorte ARAINF

(2019) Diego Casas Deza et al.   Gastroenterologia y Hepatologia

Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis

(2019) Thomas Ochsenkühn et al.   United European Gastroenterology Journal

Short and Long-Term Effectiveness of Ustekinumab in Patients with Crohn’s Disease: Real-World Data from a German IBD Cohort

(2019) Alica Kubesch et al.   Journal of Clinical Medicine

Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience

(2018) P. Wils et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Su1799 - Pregnancy Outcomes in Women Exposed to Ustekinumab

(2018) Uma Mahadevan et al.   GASTROENTEROLOGY

Mo1849 - Induction Treatment with Subcutaneous Rather than Intravenous Ustekinumab is Associated with Comparable Circulating Drug Levels and Early Clinical Response

(2018) Catherine Rowan et al.   GASTROENTEROLOGY

Mo1875 - Efficacy of Ustekinumab in Patients with Refractory Perianal Crohn's Disease in a Tertiary Care IBD Center

(2018) Venkata R. Satyam et al.   GASTROENTEROLOGY

P704 Ustekinumab induces limited mucosal healing after 6 months in a real-life, prospective cohort of patients with refractory Crohn’s disease

(2018) B Verstockt et al.   Journal of Crohns & Colitis

Ustekinumab Exposure during Conception and Pregnancy in Patients with Chronic Plaque Psoriasis - a case series of 10 pregnancies

(2018) N. Watson et al.   BRITISH JOURNAL OF DERMATOLOGY

Drug Levels in the Maternal Serum, Cord Blood and Breast Milk of a Ustekinumab-Treated Patient with Crohn’s Disease

(2018) Entcho Klenske et al.   Journal of Crohns & Colitis

Fistula Healing in Pivotal Studies of Ustekinumab in Crohn's Disease

(2017) Bruce E. Sands et al.   GASTROENTEROLOGY

P360 Trough levels and antibodies to ustekinumab are not correlated to response to ustekinumab treatment in Crohn's disease patients

(2017) P. Claire et al.   Journal of Crohns & Colitis

P640 Serum ustekinumab levels achieved with a subcutaneous induction regimen correlate to clinical outcome – a prospective study

(2017) C.R. Rowan et al.   Journal of Crohns & Colitis

Ustekinumab Drug Levels in Maternal and Cord Blood in a Woman With Crohn’s Disease Treated Until 33 Weeks of Gestation

(2017) Catherine R Rowan et al.   Journal of Crohns & Colitis

Perianal fistulizing Crohn's disease: pathogenesis, diagnosis and therapy

(2017) Julián Panés et al.   Nature Reviews Gastroenterology & Hepatology

Ustekinumab use in Crohn’s disease: a Canadian tertiary care centre experience

(2017) Astrid-Jane Greenup et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn’s Disease Refractory to Anti–Tumor Necrosis Factor Agents

(2016) Pauline Wils et al.   Clinical Gastroenterology and Hepatology

Patients with Refractory Crohnʼs Disease Successfully Treated with Ustekinumab

(2016) Kimberly A. Harris et al.   INFLAMMATORY BOWEL DISEASES

Ustekinumab for the Treatment of Refractory Crohnʼs Disease

(2016) Sam Khorrami et al.   INFLAMMATORY BOWEL DISEASES

Ustekinumab therapy for Crohn's disease during pregnancy: a case report and review of the literature

(2016) X. Cortes et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

(2016) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pregnancy during Ustekinumab Treatment for Severe Psoriasis

(2015) Katiucia Rocha et al.   DERMATOLOGY

Successful pregnancy outcome under prolonged ustekinumab treatment in a patient with Crohn's disease and paradoxical psoriasis

(2015) E. Galli-Novak et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Pregnancy outcomes of two patients exposed to ustekinumab in the first trimester

(2014) Claire Sheeran et al.   AUSTRALASIAN JOURNAL OF DERMATOLOGY

Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease—The McGill experience

(2014) U. Kopylov et al.   Journal of Crohns & Colitis

Inadvertent pregnancy during ustekinumab therapy in a patient with plaque psoriasis and impetigo herpetiformis

(2014) A. Alsenaid et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient Population

(2012) Christina Ha et al.   Clinical Gastroenterology and Hepatology

Open Label Ustekinumab for the treatment of anti-TNFα refractory moderate-to-severe Crohnʼs disease: Follow up of a cohort of patients at an academic inflammatory bowel disease center

(2012) Melissa Rosen et al.   INFLAMMATORY BOWEL DISEASES

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials

(2011) Mark Lebwohl et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease

(2010) Waqqas Afif et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Development in the cynomolgus macaque following administration of ustekinumab, a human anti-il-12/23p40 monoclonal antibody, during pregnancy and lactation

(2010) Pauline L. Martin et al.   BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY